

WELCOME
TO OUR AMAZING COMPANY

從台灣出發，拓展到全世界

PIC/S GMP 藥廠

PBF 寶齡富錦生技
Panion & BF Biotech Inc.



Panion & BF Biotech Inc. (The Company)

Disclaimer

- The presentation and the relevant information mentioned in this material, including operating performance, financial performance and the business outlook, have been compiled from both internal and external resources.
- These forward looking statements involve known and unknown risks, uncertainties and other factors, including price variation, competition, global economy, exchange rate movement and market demand, which may cause actual results to differ materially from those implied by such forward-looking statements.
- This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this Presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.
- The forward looking statements expressed in this material reflect the Company's current view about the future as of today. The Company is not responsible for any updates if there are any changes in the future.

目錄 (CONTENTS)

公司簡介(PBF INTRODUCTION)

營運成果(OPERATIONS HIGHLIGHT)

財務報告(FINANCIAL STATEMENT)

主要事業體營運概況(KEY BUSINESS UNITS AND OUTLOOK)

Q&A



目錄 (CONTENTS)

公司簡介(PBF INTRODUCTION)

營運成果(OPERATIONS HIGHLIGHT)

財務報告(FINANCIAL STATEMENT)

主要事業體營運概況(KEY BUSINESS UNITS AND OUTLOOK)

Q&A



Introduction of PBF

- 成立時間：1976年1月7日
- 上市時間：2018年1月23日 (股票代號：1760)
- 整合能力: 研發、製造、品牌、通路行銷與多角化事業群經營。
- 事業體包含: 新藥開發、西藥製藥、醫美藥粧、營養保健、專業消毒感控、動寵物、感染檢測及精準醫療、原料藥開發生產等
- 資本額: 新台幣 8.57億元
- 集團旗下生產基地
 - 台灣: 西藥廠 + 化妝品廠 + 保健食品廠 + 檢驗試劑廠 + 微針廠 + 原料藥廠
 - 中國大陸: 高規格化妝品廠&消毒用品廠
- 員工人數: 台灣約460+、海外:約70+

產品類別 (Product Categories)



六大事業體 (Six Strategic BU)

台灣寶齡
(PBF Taiwan)




創新醫療
(Innovative Medicine)

中國寶齡
(PBF China)



創新診斷
(Innovative Diagnostics)

原料藥事業
(API Business)





創新醫美
(Innovative Cosmeceuticals)

ESG

- 推動組織：本公司「總經理室」為推動永續管理，經董事會於2022年8月11日決議通過成立專責之「永續發展委員會」，由江宗明總經理擔任「永續發展委員會」主任委員，並擬定溫室氣體減碳的短、中、長期目標。

- 近期成果：

- ✓ 2023/08- 通過溫室氣體盤查及查證 (2022年度) [本公司]
- ✓ 2024/06- 通過溫室氣體盤查及查證 (2023年度) [包含海外公司]
- ✓ 2024/08- 發布永續報告書 (2023年度)

bsi.  

Opinion Statement

Greenhouse Gas Emissions Verification Opinion Statement


This is to verify that: Panion & BF Biotech Inc. 寶齡富錦生技股份有限公司
16F. 臺灣
No. 3, Park St. 台北市
Nangang Dist. 南港區
Taipei City 南港區 3 號
115603 18 樓
Taiwan 115603

Holds Statement No: GHGEV 791889
Verification opinion statement

As a result of carrying out verification procedures in accordance with ISO 14064-3:2006, it is the opinion of BSI, with reasonable assurance that:

- The Greenhouse Gas Emissions with Panion & BF Biotech Inc. for the period from 2022-01-01 to 2022-12-31 was verified, including direct greenhouse gas emissions 278,544 tonnes of CO₂ equivalent and indirect greenhouse gas emissions from imported energy emissions 5,157,732 tonnes of CO₂ equivalent.
- Emissions calculation were reviewed.
- Data quality was considered acceptable in meeting the principles as set out in ISO 14064-1:2018.
- The emission factor for electricity of year 2022 is 0.495 kgCO₂e per kWh by Taiwan government, and the electricity emission factor from TA-YUAN COGEN CO., LTD. of year 2022 is 0.7667047261 kgCO₂e per kWh; the steam emission factor from TA-YUAN COGEN CO., LTD. of year 2022 is 0.2713104902 tonne CO₂e per tonne.

The other selected indirect GHG emissions listed in the attached table on the next page were also reported and thus verified with limited assurance, and data quality was not considered unacceptable in meeting the principles as set out in ISO 14064-1: 2018.

For and on behalf of BSI: 
Managing Director BSI Taiwan, Peter Pu

Originally Issue: 2023-08-30 Latest Issue: 2023-08-30 Page: 1 of 3

...making excellence a habit.™

The British Standards Institution is independent of the above named client and has no financial interest in the above named client. This Opinion Statement has been prepared for the above named client only for the purposes of verifying its statements relating to its carbon emissions from particular processes described in the scope. It was not prepared for any other purpose. The British Standards Institution will not, in providing this Opinion Statement, accept or assume responsibility (legal or otherwise) or any other liability for any other purpose for which it may be used or by any person who claims the Opinion Statement may be used. This Opinion Statement is prepared on the basis of review by The British Standards Institution of information presented to it for the above named client. The issuer does not intend to provide such information and is solely based on it. In performing such review, The British Standards Institution has assumed that all such information is complete and accurate. Any queries that may arise by virtue of this Opinion Statement or system relating to it should be addressed to the above named client only.
Taiwan Headquarters: 200 Floor, No. 17, 2/F, Rd. 1st, Sec 4, Taipei 114, Taiwan, R.O.C.
UK: Twicken is a subsidiary of British Standards Institution.

Statement No:	GHGEV 791889
Location	Verification Information
Panion & BF Biotech Inc. 16F. No. 3, Park St. Nangang Dist. Taipei City 115603 Taiwan 寶齡富錦生技股份有限公司 臺灣 台北市 南港區 南港區 3 號 115603	The Direct GHG Emissions and Removals with: Panion & BF Biotech Inc. for the period from 2022-01-01 to 2022-12-31 is 278,544 tonnes of CO ₂ equivalent, and the Indirect GHG Emissions from Imported Energy is 5,157,732 tonnes of CO ₂ equivalent. Including Headquarters, Pingzhen Plant, Xizhi Plant, Xike Plant, and Dayuan Plant of Cheng Feng Chemical Co., Ltd., a total of 5 locations. 包括總公司、平鎮廠、汐止廠、微針沙林廠、正峰化學製藥股份有限公司大園廠，共 5 個據點。

Originally Issue: 2023-08-30 Latest Issue: 2023-08-30 Page: 3 of 3

The British Standards Institution is independent of the above named client and has no financial interest in the above named client. This Opinion Statement has been prepared for the above named client only for the purposes of verifying its statements relating to its carbon emissions from particular processes described in the scope. It was not prepared for any other purpose. The British Standards Institution will not, in providing this Opinion Statement, accept or assume responsibility (legal or otherwise) or any other liability for any other purpose for which it may be used or by any person who claims the Opinion Statement may be used. This Opinion Statement is prepared on the basis of review by The British Standards Institution of information presented to it for the above named client. The issuer does not intend to provide such information and is solely based on it. In performing such review, The British Standards Institution has assumed that all such information is complete and accurate. Any queries that may arise by virtue of this Opinion Statement or system relating to it should be addressed to the above named client only.
Taiwan Headquarters: 200 Floor, No. 17, 2/F, Rd. 1st, Sec 4, Taipei 114, Taiwan, R.O.C.
UK: Twicken is a subsidiary of British Standards Institution.

目錄 (CONTENTS)

公司簡介(PBF INTRODUCTION)

營運成果(OPERATIONS HIGHLIGHT)


財務報告(FINANCIAL STATEMENT)

主要事業體營運概況(KEY BUSINESS UNITS AND OUTLOOK)

Q&A




合併綜合損益表 2020-2023年



	2020年	2021年	2022年	2023年
營業收入	1,568,637	1,901,211	2,398,648	1,881,875
營業毛利	795,123	912,138	1,318,596	974,397
稅前淨利	89,406	182,652	333,409	168,711
本期淨利	27,901	104,402	182,345	77,219
每股盈餘(元)	0.36	1.32	2.13	0.90
研發費用	127,016	157,711	248,496	217,041
佔營業收入淨額%	8.1%	8.3%	10.4%	11.5%

合併產品別營業收入 2020-2023年




產品	藥品		食品		化妝品		銷售權利金		檢驗試劑		原料藥		其他(註1)		合計	
2020年	747,769	48%	125,718	8%	290,565	19%	360,796	23%	36,374	2%	2,271	0%	5,144	0.3%	1,568,637	100%
2021年	719,660	38%	163,910	9%	263,391	14%	319,789	17%	313,144	16%	116,802	6%	4,515	0.2%	1,901,211	100%
2022年	724,221	30%	183,929	8%	161,267	7%	409,919	17%	724,634	30%	189,909	8%	4,769	0.2%	2,398,648	100%
2023年	740,492	39%	295,732	16%	219,255	12%	405,235	22%	80,774	4%	131,446	7%	8,941	0.5%	1,881,875	100%

註1：其他-醫美醫材產品。

PIC/S GMP 藥廠


合併綜合損益表

2023年同期比



	2022年(A)	2023年(B)	單位:新台幣仟元	
			2023年 VS. 2022年	
			差異金額 (B)-(A)	成長率%
營業收入	2,398,648	1,881,875	(516,773)	(22)
營業毛利	1,318,596	974,397	(344,199)	(26)
稅前淨利	333,409	168,711	(164,698)	(49)
本期淨利	182,345	77,219	(105,126)	(58)
每股盈餘(元)	2.13	0.90	(1.23)	(58)
研發費用	248,496	217,041	(31,455)	(13)
佔營業收入淨額%	10.4%	11.5%		

合併產品別營業收入 2023年同期比



產品	藥品		食品		化妝品		銷售權利金		檢驗試劑		原料藥		其他(註)		合計	
2022年(A)	724,221	30%	183,929	8%	161,267	7%	409,919	17%	724,634	30%	189,909	8%	4,769	0.2%	2,398,648	100.0%
2023年(B)	740,492	39%	295,732	16%	219,255	12%	405,235	22%	80,774	4%	131,446	7%	8,941	0.5%	1,881,875	100.0%
差異金額(B)-(A) 及成長率%	16,271	2%	111,803	61%	57,988	36%	(4,684)	-1%	(643,860)	-89%	(58,463)	-31%	4,172	87%	(516,773)	-22%

註1:其他-醫美醫材產品。

PIC/S GMP 藥廠

PBF 寶齡富錦生技
Panion & BF Biotech Inc.

目錄 (CONTENTS)

公司簡介(PBF INTRODUCTION)

營運成果(OPERATIONS HIGHLIGHT)

財務報告(FINANCIAL STATEMENT)

主要事業體營運概況(KEY BUSINESS UNITS AND OUTLOOK)

Q&A



Innovative Medicine

創新醫療事業群

NEPHOXIL PHARMACEUTICAL GRADE FERRIC CITRATE

ACCUMULATED SALES SINCE 2015
>1.3 BILLION USD

2023 GLOBAL SALES IN US&JAPAN
>220 MILLION USD




Ferric Citrate USA

Auryxia Tablets Growth

- Fourth quarter 2023 Auryxia® (ferric citrate) net product revenues of \$53.2 million and
- Full year 2023 revenues of \$170.3 million
- Expect revenue growth in 2024
- ~Q2 2025 generic entry
- Potential revenue upside in 2025 and 2026 due to phosphate binders are added to the bundle payment and eligible for Transitional Drug Add-on Payment Adjustment (TDAPA).

Source : www.Akebia.com




Ferric Citrate Japan

Riona tablets Growth

- 2023 total sales 7515 million yen
- 2023 to 2022 YoY Growth Rate : 8.3%
- 2024 estimate 6700 million yen due to 2024 NHI drug price revision.

Source : <https://www.torii.co.jp>



拿百磷多角度劑型發展

Nephoxil New Formulation Development



膠囊劑型 Capsules

- 500 毫克劑型: 透析患者使用
 - 高血磷症



錠片劑型 Tablets

- 1,000 毫克劑型: 透析前患者使用
 - 缺鐵性貧血



新口服液態 Oral Drops

- 口服液態劑型: 寵物腎病使用
 - 腎病日常照護，僅需數毫升口服或混入飲食。



拿百磷亞太地區發展

Nephoxil Cap Asia Pacific Development

- 2024 持續擴大銷售渠道與營收。
Market Expansion

Korea



Kyowa Kirin Korea
協和麒麟韓國

- 新藥審查中
NDA Review in Progress

China



Wego PBF China
威高寶齡中國

- 2024 渠道佈建，
Q3上市規劃。
Q3 Launch planned

Thai



DKSH Thai
大昌華嘉泰國



2023 拿百磷台灣 新劑型+新適應症

- 2023: 完成拿百磷**缺鐵性貧血**「新劑型+新適應症」三期臨床解盲，近期已完成衛福部三期臨床結案查核。Completion of Phase III clinical trials and TFDA investigation in 2023.
- 2024: CMC 批量試製、藥品上市申請準備與健保給付平行審查準備。Scale up production trials, CMC consolidation, and initiate product registration alongside with National Health Insurance submission for 2024.

NephoPet

Ferric Citrate Hydrate Oral Drops

82萬 寵物貓
CAGR16.63%
Taiwan

48.5萬
老齡寵物貓
>10歲
59.2%*

14.55萬
腎病寵物貓
~30%**

~9萬
人類透析
病患
Taiwan

- 專利成分+便利劑型+風味調製
- 臨床實證: NephoPet 臨床收案執行中，為全球首次針對腎病貓犬之腎病照護臨床試驗。
- 完成產品線整合，預計今年上市
 - Renal Care
 - Bone & Joint Care
 - Skin care
 - Infection Control
 - Anesthetics
- 寵物飲食市場規模達新台幣235億 台經院2022
- 腎衰竭為家貓十大死因第一位，家犬為第六位。

*財政部 **新世代寵物消費趨勢 資策會2021年問卷

原料藥產能擴充

API manufacturing capacity expansion

- 基礎產線: Max 10 ton/year 產能提升已完成，將更新US DMF
- 擴增產線: Max 100 ton/year
 - 獨棟廠房與設備建置完成
 - 批量大小: up to 5x
 - 批次時間: up to 7x
 - Q2/2024 產線試車
 - 預計今年提交TFDA投產審查與新增US DMF

Innovative Diagnostics

創新診斷事業群





In vitro diagnostics

vstrip 飛確

江政儒
寶齡創新診斷
2024/04/11

近程產品線



呼吸道病原Respiratory Pathogen

- ✓ 新型冠狀病毒 (Sars-Cov-2)
- ✓ 流感病毒(Influenza Virus)
- ✓ 呼吸道融合病毒(RSV)
- ✓ 腺病毒(Adenovirus)
- ✓ A型鏈球菌(GAS)
- 人類間質肺炎病毒(hMPV)
- 嗜肺性退伍軍人桿菌(l. Pneumophila)
- 肺炎鏈球菌(s. Pneumoniae)
- 肺炎黴漿菌(m. Pneumoniae)

腸胃道病原Gastrointestinal Pathogen

- ✓ 幽門螺旋桿菌(h. Pylori)
- ✓ 輪狀病毒(Rotavirus)
- ✓ 腺病毒(Adenovirus)
- 困難梭狀桿菌(c. Difficile)
- 諾羅病毒(Norovirus)
- 腸病毒(Enterovirus)

其他Others

- ✓ 乙型鏈球菌(GBS)
- ✓ 糞便潛血(FOB)
- ✓ 登革熱病毒(Dengue Virus)
- 抗穆氏管荷爾蒙(AMH)

中長程產品線



性傳染病原STD Pathogen

- 人類免疫缺乏病毒(HIV)
- 梅毒(Syphilis)
- 淋病(Gonorrhea)
- 猴痘(Monkeypox)

癌症指標Cancer Marker

- CA72-4
- CA125
- CA15-3
- CA199
- PSA

抗藥細菌檢測

Antimicrobial Susceptibility Testing

心臟指標Cardiac Marker

- 心肌鈣蛋白(Troponin)
- B型利鈉利尿胜肽(BNP)
- 肌酸磷酸酶(CK-MB)

發炎指標Inflammation Marker

- 前降鈣素(PCT)
- C反應蛋白(CRP)

30分鐘內取得結果 加速醫療決策



COVID
Flu A
Flu B



COVID
Flu A
Flu B
RSV




COVID
Flu A
Flu B
RSV
ADV

Multiplex Detection 多合一檢測

一次採檢，多重檢測

2024 Clinical Study of Multiplex Rapid Test in US





Vstrip NANA

檢測判讀機

適用Vstrip快篩、微流晶片

使用場域

- 診所
- 醫院
- 長照機構
- 到宅醫療
- 學校

自動化判讀 減少檢驗操作流程

時程

台灣TW

查驗登記送件Registration

- 2023Q2 飛確RV2 新冠抗原快篩(專業版)
- 2023Q2 飛確RV2 新冠抗原快篩(家用版)
- 2023Q3 研準新冠抗原快篩(家用版)中研院委託開發
- 2024Q1 飛確登革熱抗原快篩試劑
- 2024Q1 飛確ABC(流感/新冠)抗原快篩
- 2024Q1 飛確糞便潛血(FOB)抗原快篩試劑
- 2024Q3 飛確肺炎鏈球菌抗原快篩試劑
- 2024Q3 飛確退伍軍人菌抗原快篩試劑
- 2024Q3 飛確困難梭菌抗原快篩試劑

新加坡SG

查驗登記送件Registration

- 2024 飛確ABC(流感/新冠)抗原快篩
- 2024 飛確登革熱抗原快篩試劑

泰國TH

查驗登記送件Registration

- 2024 飛確糞便潛血(FOB)抗原快篩試劑

美國US

臨床試驗執行Clinical Study

- 2024 ABCR(流感/新冠/呼吸道融合病毒) 抗原快篩

加拿大CA

查驗登記送件Registration

- 2024 飛確幽門螺旋桿菌抗原快篩

瓜地馬拉GT

查驗登記送件Registration

- 2023Q1 飛確RV2 新冠抗原快篩
- 2024Q1 飛確流感抗原快篩


策略

- 產品線擴增
- 台灣臨床合作、技術開發合作建立
- 多重檢測
- 操作/判讀流程自動化
- 美、加、瓜、新、泰取證、提供ODM服務
- 照護點或居家30分鐘內檢驗完成



我們關注的

Global Warming



Burnout Medical Personnel



Drug Resistant Bacterial



串聯台灣上下游合作 強化台灣醫學檢驗能量

抗原快篩 Antigen Test

- 傳染病檢驗 (Infectious Disease)

自動化判讀 Reader

自動化微流晶片 Microfluidic Chip

- 心臟指標檢驗 (Cardiac Marker)
- 發炎指標檢驗 (Inflammation Marker)
- 腫瘤指標檢驗 (Tumor Marker)

2023

2024

2025

2014

分子檢測 Molecular Test

- 傳染病檢驗 (Infectious Disease)

LDT 認證

- 傳染病檢驗

照護點 & 居家檢驗


Point of Care Testing & Home Testing

Vstrip 飛確
讓檢驗變得簡單

Innovative Cosmeceuticals

創新醫美事業群





Innovative Aesthetics Department



(微創醫美) 產品發展進度

A. 注射

產品名稱	專利/ know-how	發展進度	目前 市場潛力
寶齡富錦 聚左旋乳酸微米球	微球製程專利 (大小規則具孔洞的可降解微球)	台北醫學大學臨床試驗進行中 TFDA核准 臨床試驗第 1120704614 號 預計2025年中完成Pilot Study，2026年底前取證	148億 美元

產品	市售品 	寶齡富錦 聚左旋乳酸微米球 
特徵	<ol style="list-style-type: none"> 1. 不規則微粒，容易塞針 2. 需2小時回溶時間，使用便利性差 	<ol style="list-style-type: none"> 1. 大小規則具孔洞可降解微球，不塞針 2. 回溶時間少於10分鐘，使用便利 3. 動物試驗證實低發炎性
電顯圖		



PIC/S GMP 藥廠

PBF 寶齡富錦生技
Panion & BF Biotech Inc.

(微創醫美) 產品發展進度


B. 埋線

產品名稱	專利/ know-how	發展進度	目前 市場潛力
AmazLine® 保媯妍® 1.可吸收性縫線 2.拉提線	鑄模線雕(非切割線) · 一體成形	1. 吸收縫線已取證 2. 拉提線即將取證 · 預計2024/Q4上市	66億 美元



鑄壓塑型，一體成形

- 鑄模製程，一體成形
- 雙向錨狀倒鉤，結構完整、拉提力強
- 可維持12-18個月




(半微創醫美) 產品發展進度

C. 微針

產品名稱	專利/ know-how	發展進度	目前 市場潛力
兩段式微針 1. 淡斑微針(450μm) 2. 紋繡微針(450μm) 3. 除皺微針(600μm)	1.微針裝置及其製法 2.皮膚貼片 (設計專利)	1. 淡斑微針已小量試產 2. 紋繡微針預計2024/Q2上市 3. 除皺微針(含PLLA微球)，已完成動物(大鼠)膠原增生效果試驗，成大合作技術轉移中	108億 美元

兩段式微針示意圖



針長：450μm, 600μm
產品尺寸：微針方格1*1cm
針數：196根/片



6 Piece

1. 淡斑微針(450um)




小分子玻尿酸+
淡斑活性成分

高強度底座



2. 紋繡微針




頭頂分線

髮際線

瞬間轉變，自然濃密，取代醫生用的SMP手術


紋繡微針可藉由微針穿刺方式，將染料傳遞至表皮層，形成類髮絲的外觀和質感，從而在頭皮上創造出一種自然濃密的髮型效果。

3. 除皺微針(含PLLA微球)



微針穿刺大鼠後三個月

第三型膠原蛋白量化結果



(半微創醫美) 產品發展進度

D. 外泌體+PRP

產品名稱	專利/ know-how	發展進度	目前 市場潛力
PxoBang®培可棒 外泌體凍晶	1.萃取技術 2.活性保護技術	(外泌體+PRP)萃取的INCI Name申請中(Porcine platelet derived exosomes) · 預計2024/10可以取得	NEW


唯一複合式凍晶：(外泌體+PRP)凍晶

每1.1mg
(外泌體+PRP)
凍晶


成分	含量
Exosomes	3.92億顆
PDGF	1 ± 0.1 ng
TGF-Beta1	7.5 ± 0.7 ng
EGF	0.25 ± 0.025 ng
VEGF	0.25 ± 0.025 ng
b-FGF	0.1 ± 0.01 ng

定性定量：依據不同使用需求可增減濃度


專利萃取技術



專利活性保護技術



安定性實證



/S GMP 藥廠


BF 寶齡富錦生技
Panion & BF Biotech Inc.

(無創醫美) 產品發展進度

E. 複合分子量玻尿酸


技術名稱	專利/ know-how	發展進度	目前 市場潛力
熱裂解玻尿酸 (複合分子量玻尿酸 製劑) 5D, others	1. 熱裂解技術專利 2. 多角度光散射分析(分子量)技術	2024/Q1已上市	NEW

熱裂解玻尿酸



- 1. 包含多種分子量，達到皮膚不同深度
- 2. 可依照需求客製化分子量分布

不同分子量的玻尿酸，可深入不同層次皮膚層



> 2000 KDa

300-500 KDa

100-200 KDa

50-100 KDa

20-50 KDa

PBF 寶齡富錦生技
Panion & BF Biotech Inc.

目錄 (CONTENTS)

公司簡介(PBF INTRODUCTION)

營運成果(OPERATIONS HIGHLIGHT)

財務報告(FINANCIAL STATEMENT)

主要事業體營運概況(KEY BUSINESS UNITS AND OUTLOOK)

Q&A



健康 分享 關懷

寶齡相信，人人都應盡情享受生命的美好！

